Translational Lung Research Center Heidelberg (TLRC)
Five partner institutions participate in the DZL site TLRC:
Heidelberg University Hospital
Thoraxklinik at Heidelberg University Hospital
German Cancer Research Center (DKFZ)
European Molecular Biology Laboratory (EMBL)
TLRC in Heidelberg aims to improve diagnostics and therapy of chronic lung diseases of children and adults in close exchange between basic and clinical research.
Research is focused on the mechanisms underlying common genetic and acquired chronic and malignant lung diseases, such as Cystic Fibrosis (CF), COPD, and Lung Cancer. TLRC scientists also contribute to research in the fields of Asthma and Allergy, Pulmonary Fibrosis, Pneumonia and Acute Lung Injury, and Pulmonary Hypertension. The scientists’ goal is to identify new therapeutic targets to improve diagnostics and develop further curative treatment options. Within the basic research program, cell and animal models are used to investigate molecular causes of chronic airway diseases. Use is made of next-generation sequencing as well as state-of-the art immunobiology and molecular biology techniques. Current research investigates the mechanisms leading to airway mucus obstruction and chronic inflammation in Cystic Fibrosis and other chronic obstructive pulmonary diseases, such as COPD and Asthma. At the TLRC, systems biology is applied to improve our understanding of the molecular causes of Lung Cancer. The Biobanking and Imaging platforms are crucial to the success of the translational lung research program. Early clinical trials are conducted to make new diagnostic and therapeutic strategies available to patients as early as possible.
Director of TLRC is Prof. Dr. Hans-Ulrich Kauczor. He is supported by Dr. Birgit Teucher as DZL manager.